Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20524392 | 0.85 | TRPV1 (0.44) | JAK3 | |
| SCHEMBL20520106 | 0.85 | TRPV1 (0.44) | JAK3 | |
| SCHEMBL13703136 | 0.83 | JAK3 (0.56) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL13703442 | 0.83 | JAK3 (0.56) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL13703137 | 0.83 | JAK3 (0.56) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL390147 | 0.83 | SYK (0.53) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL389068 | 0.83 | SYK (0.53) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL389069 | 0.83 | SYK (0.53) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL29849700 | 0.82 | SUV39H2 (0.52) | SUV39H2SYKBTKJAK3CKS1B | |
| SCHEMBL20520113 | 0.81 | USP30 (0.47) | SUV39H2SYKBTKJAK3CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| CN-110678466-B | Diazanaphthalenes as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3601284-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678466-A | Naphthyridines as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | SUV39H2 2304/4885SYK 4008/4885BTK 4082/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | SUV39H2 2304/4885SYK 4008/4885BTK 4082/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | SUV39H2 2304/4885SYK 4008/4885BTK 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.